The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Fosun Pharma; GenomiCare; Hutchison MediPharma; InventisBio; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study.
 
Yongfeng Yu
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Wei Zhang
No Relationships to Disclose
 
Dongqing Lv
No Relationships to Disclose
 
Yuan Chen
No Relationships to Disclose
 
Dingzhi Huang
No Relationships to Disclose
 
Mingjun Zhang
No Relationships to Disclose
 
Yongsheng Li
No Relationships to Disclose
 
Dairong Li
No Relationships to Disclose
 
Junzhen Gao
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Zhiyong He
No Relationships to Disclose
 
Jianhua Shi
No Relationships to Disclose
 
Mingfang Zhao
No Relationships to Disclose
 
Anwen Liu
No Relationships to Disclose
 
Chunyue Wang
No Relationships to Disclose
 
Hui Zhu
No Relationships to Disclose
 
Shun Lu
No Relationships to Disclose